LIVMARLI in the United States

Livmarli TM logo

LIVMARLI (maralixibat) oral solution

LIVMARLI (maralixibat) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older.

Connect with experts from the Mirum Access Plus program who can help secure access for patients and families. GET STARTED


Learn more about LIVMARLI in Europe Learn more about LIVMARLI in Canada

Important Safety Information

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

  • nausea or vomiting
  • skin or the white part of the eye turns yellow
  • dark or brown urine
  • pain on the right side of the stomach (abdomen)
  • loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were bone fractures and gastrointestinal bleeding.

Prescribing Information

Mirum Access Plus (MAP)

Designed to help patients and families navigate the LIVMARLI (maralixibat) treatment journey, MAP experts provide support in the following ways:

  • Explain the process of getting medication
  • Work with dedicated healthcare teams to figure out insurance coverage and eligibility for financial support programs
  • Provide education and resources to help patients start and stay on therapy

If you have questions about MAP, contact the navigators at: 1-855-MRM-4YOU
(1-855-676-4968)
Monday to Friday
8:00 a.m. – 8:00 p.m. ET